A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Public ClinicalTrials.gov record NCT01776307. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open label, multi-center, Phase 2 study of BBI608 in combination with cetuximab, panitumumab or capecitabine in patients with advanced colorectal cancer.
Study identification
- NCT ID
- NCT01776307
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 200 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 29, 2012
- Primary completion
- May 31, 2018
- Completion
- Mar 31, 2020
- Last update posted
- Nov 14, 2023
2012 – 2020
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic | Scottsdale | Arizona | 85259 | — |
| USOR - Rocky Mountain Cancer Center | Denver | Colorado | 80218 | — |
| Mayo Clinic | Jacksonville | Florida | 32224 | — |
| USOR - Minnesota Oncology Hematology | Minneapolis | Minnesota | 55404 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| The Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
| USOR - Northwest Cancer Specialists | Portland | Oregon | 97227 | — |
| Abramson Cancer Center of the University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Institute for Translational Oncology Research, Greenville Hospital System | Greenville | South Carolina | 29605 | — |
| USOR - Texas Oncology Dallas | Dallas | Texas | 75246 | — |
| US Oncology Research | The Woodlands | Texas | 77380 | — |
| USOR - Texas Oncology Tyler | Tyler | Texas | 75702 | — |
| USOR - Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01776307, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 14, 2023 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01776307 live on ClinicalTrials.gov.